EGFR and esophageal squamous cell carcinoma: An AIO/EORTC POWER phase III trial randomized 146 ESCC patients with advanced disease to receive chemotherapy (cisplatin plus 5-fluorouracil) alone or chemotherapy plus panitumumab (an anti-EGFR mAb); however, the addition of panitumumab did not improve survival, and the study was stopped early due to a higher mortality rate in the panitumumab-treated group [65].